atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference | Psychedelic Invest

NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai’s supervisory board (“Board”) subject to applicable legal requirements. Scott…

Astellas to Acquire Iveric Bio for $5.9B, Expanding Eye Disease Pipeline

Astellas Pharma president and CEO Naoki Okamura Astellas Pharma has agreed to acquire Iveric Bio for approximately $5.9 billion, the companies said today, in a

May 1, 2023

Childhood diabetes rates surge globally

Researchers investigate global trends in childhood diabetes rates and different factors that contribute to its incidence.

December 4, 2024

Gabapentin as Post-Op Painkiller Gets a Cold Shower

SAN FRANCISCO — Gabapentin failed to outperform placebo as an analgesic for pain after major surgery, according to a study presented here. No clinically significant

October 16, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.